KW-8232 free base|170365-25-0|-陌孚医药/Medlife

您当前的位置：

KW-8232 free base

目录号: PL10129 纯度: ≥95.0%

CAS No. :170365-25-0

商品编号	规格	价格	会员价
PL10129-1mg	1mg	¥13661.00	请登录
PL10129-5mg	5mg	询价	询价
PL10129-10mg	10mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	KW-8232 free base
中文别名	化合物 T11792
英文名称	KW-8232 free base
英文别名	KW-8232 free base;TG6XB829KQ;Kw 8232;BK177443;[1-[2-(Dimethylamino)ethyl]-3-(4,4'-dihydroxybenzhydryl)-1H-indole-2-yl][4-(2-chlorophenyl)-1-piperazinyl] ketone;[3-[bis(4-hydroxyphenyl)methyl]-1-[2-(dimethylamino)ethyl]indol-2-yl]-[4-(2-chlorophenyl)piperazin-1-yl]methanone;Methanone, (3-(bis(4-hydroxyphenyl)methyl)-1-(2-(dimethylamino)ethyl)-1H-indol-2-yl)(4-(2-chlorophenyl)-1-piperazinyl)-;Piperazine, 1-((3-(bis(4-hyd;Methanone, [3-[bis(4-hydroxyphenyl)methyl]-1-[2-(dimethylamino)ethyl]-1H-indol-2-yl][4-(2-chlorophenyl)-1-piperazinyl]-
Cas No.	170365-25-0
分子式	C₃₆H₃₇ClN₄O₃
分子量	609.16
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	KW-8232 free base是一种具有口服活性的抗骨质疏松剂，可以减少前列腺素 PGE2 的生物合成。
生物活性	KW-8232 free base, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.
性状	Solid
IC50 & Target[1][2]	Prostaglandin Receptor
体外研究(In Vitro)	KW-8232 is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE2 in mouse osteoblastic cells. KW-8232 possesses anti-viral activity against SARS-CoV-2 (EC50 ~1.2 μM ). has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnovrer. KW-8232 markedly decreases urinary calcium excreation in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridionline excretion which are markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Uchii M, et al. Effect of KW-8232, a novel anti-osteoporotic agent, on bone loss in sciatic neurectomized rats. Jpn J Pharmacol. 1998 Oct;78(2):241-3. [2]. Shiwei Wang, et al. A Transferable Deep Learning Approach to Fast Screen Potent Antiviral Drugs against SARS-CoV-2. bioRxiv. 2020.

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation